Clinical trial
Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers
NCT02279602 is registered in ClinicalTrials.gov with Mateon Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers
- Lead sponsor
- Mateon Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2014
- Completion date
- August 31, 2016
- Enrollment
- 7 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.